Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to solve the grand challenge of in vivo gene delivery, today announced that Astellas Pharma Inc. (TSE: ...
40 million people live with HIV globally, and that number continues to rise. While therapies exist to reduce the amount of HIV in a patient's body and, in turn, reduce HIV symptoms, there remains no ...
Joseph La Barge has been mulling over the limitations of gene therapy for some time. So, when he left his position at Spark Therapeutics, having watched the company grow from its start in borrowed ...
(RTTNews) - Voyager Therapeutics, Inc. (VYGR), a developer of adeno-associated virus or AAV capsids, announced Tuesday a license option agreement, under which Novartis (NVS) will receive ...
In viral capsids, T=3 and T=4 refer to the triangulation number, a value that describes how protein subunits are arranged to build a larger, stable, icosahedral structure. A higher number corresponds ...
WALTHAM, Mass.--(BUSINESS WIRE)--Affinia Therapeutics (“Affinia”), an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies ...
- Oral presentation on tau silencing gene therapy VY1706, which has previously shown up to 73% knockdown of tau mRNA in NHPs in the CNS following a single IV dose of 1.3e13 vg/kg - - Featured data ...
The possibilities for gene therapies are being realized as candidates come to market with hundreds more in development. Adeno-associated virus (AAV) is a common vector, yet current production, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results